Advertisement

Topics

SillaJen Announces Collaboration With TheNCI For Development Of Combination Therapy With s Pexastimogene Devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

20:00 EDT 16 Aug 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: SillaJen Announces Collaboration With TheNCI For Development Of Combination Therapy With s Pexastimogene Devacirepvec (Pexa-Vec) Oncolytic Immunotherapy

NEXT ARTICLE

More From BioPortfolio on "SillaJen Announces Collaboration With TheNCI For Development Of Combination Therapy With s Pexastimogene Devacirepvec (Pexa-Vec) Oncolytic Immunotherapy"

Advertisement
Quick Search
Advertisement
Advertisement